SAB Biotherapeutics appoints Erick Lucera, former AVEO CFO, to Board of Directors

SAB Biotherapeutics, Inc.

Erick Lucera appointed to SAB Biotherapeutics Board effective April 4, 2023; term until next annual meeting.
Lucera most recently served as CFO of AVEO Oncology through its acquisition by LG Chem; prior CFO at Valeritas and Viventia Bio.
With 30+ years in biotech/med device finance, he brings experience in corporate finance, M&A, and public offerings.
Compensation consistent with other non-employee directors as described in the 2022 proxy statement.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Erick Lucera

Director

SABS · SAB Biotherapeutics, Inc.

Effective: 2023-04-03
Filed: April 4, 2023, 7:59 PM ET

the Board subsequently appointed, Mr. Erick Lucera to serve as a director of the Company, effective as of April 3, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Erick Lucera was appointed as Director at SAB Biotherapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board subsequently appointed, Mr. Erick Lucera to serve as a director of the Company, effective as of April 3, 2023

View on SEC.gov

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-009184

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.